Clinical trials: Weight Loss
Obesity
A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)
This study will look at how much weight participants will lose from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in…
- Trial name
- STEP UP (NCT05646706)
- Testing
- Semaglutide
- Where
- 107 sites in United States, Bulgaria and 10 more
- Volunteers
- 1,407 people
- Sponsor
- Novo Nordisk A/S
Cachexia, Non-Small Cell Lung Cancer
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
The administration of Anamorelin in patients with Stage III-IV non-small cell lung cancer-cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength.
- Trial name
- NCT01387282
- Testing
- Anamorelin HCl
- Where
- 46 sites in United States, Australia and 5 more
- Volunteers
- 495 people
- Sponsor
- Helsinn Therapeutics (U.S.), Inc
Hypercatabolic Status Related to Severe Burn
Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects
Study of tolerability and efficacy of BVS857 in severe burn subjects over 8 weeks and 15 weeks
- Trial name
- NCT02074995
- Testing
- BVS857
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Novartis Pharmaceuticals
Obesity
The Safety and Efficacy of vBloc Therapy Delivered by the Maestro Rechargeable System for the Treatment of Obesity
The study evaluated the safety and efficacy of the vBloc Therapy delivered by the Maestro Rechargeable System compared to a sham control for the treatment obesity.
- Trial name
- ReCharge (NCT01327976)
- Testing
- vBloc (Active Device)
- Where
- 10 sites in United States, Australia
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- ReShape Lifesciences
Overweight and Obesity
Safety and Efficacy of the SMART Device for Overweight and Obese Adults
The purpose of this study is to demonstrate that (1) we will observe at least 40% of the subjects in the Per Protocol population having a measured ≥5% weight loss at 16 weeks compared to week 0; and (2) the observed mean % Total…
- Trial name
- SMART (NCT02119299)
- Testing
- SMART device
- Where
- 4 sites in United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Scientific Intake Limited Co.
Obesity, Overweight
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
This is a study of LY3437943 in participants who have obesity or are overweight. The main purpose is to learn more about how LY3437943 affects body weight loss. The study will last about 18 months and may include up to 18 visits.
- Trial name
- NCT04881760
- Testing
- LY3437943
- Where
- 28 sites in United States, Puerto Rico
- Volunteers
- 338 people
- Sponsor
- Eli Lilly and Company
Pro-opiomelanocortin (POMC) Deficiency Obesity
Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity
To demonstrate statistically significant and clinically meaningful effects of setmelanotide on percent body weight change in participants with pro-opiomelanocortin (POMC) deficiency or proprotein convertase subtilisin/kexin type…
- Trial name
- NCT02896192
- Testing
- Setmelanotide
- Where
- 7 sites in United States, Belgium and 5 more
- Volunteers
- 15 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Obesity
LapBand Adjustment to Improve Early Weight Loss
Subjects having a gastric band fitted will have the first band adjustment done at surgery. The stoma will be set to 7mm using the EndoFLIP system to measure stoma size.
- Trial name
- NCT01060592
- Testing
- EndoFLIP device (FDA Device Listing Number : D091203)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Crospon
Cachexia
SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)
To evaluate SUN11031 for subcutaneous injection compared to placebo in subjects with cachexia associated with Chronic Obstructive Pulmonary Disease (COPD) to determine the effect on physical performance and body composition.
- Trial name
- NCT00698828
- Testing
- SUN11031 20 μg/kg, SUN11031 40 μg/kg
- Where
- 43 sites in United States, Argentina and 4 more
- Volunteers
- 227 people
- Sponsor
- Daiichi Sankyo
Obesity
A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833
This is a study to evaluate the safety and efficacy of K-757 alone and in combination with K-833 versus placebo in participants who are obese.
- Trial name
- NCT06019559
- Testing
- K-757 120 mg BID and K-833 100 mg BID
- Where
- 22 sites in United States
- Volunteers
- 155 people
- Sponsor
- TriGemX Bio, Inc.
Obesity
A Multicenter Study for Pre-Surgical Weight Loss
The purpose of the study is to evaluate the safety and initial efficacy of the EndoBarrier device compared to a diet control in patients who require weight loss prior to their Bariatric surgery.
- Trial name
- NCT00830440
- Testing
- EndoBarrier Device, Diet & Lifestyle Counseling
- Where
- Netherlands
- Volunteers
- 43 people
- Sponsor
- Morphic Medical Inc.
Obesity
BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus
The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients with Type II diabetes mellitus treated with metformin, sulfonylurea (SFU)…
- Trial name
- NCT00603291
- Testing
- Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID)
- Where
- United States
- Volunteers
- 604 people
- Sponsor
- Eisai Inc.
Cachexia; Cancer, Non Small Cell Lung Cancer
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 2
The goal of this clinical trial was to compare the efficacy and safety of anamorelin HCl (the investigational drug) to that of placebo (tablet with no drug) in patients with advanced non-small cell lung cancer and cachexia…
- Trial name
- NCT03743064
- Testing
- anamorelin HCl
- Where
- 65 sites in United States, Australia and 6 more
- Volunteers
- 318 people
- Sponsor
- Helsinn Healthcare SA
Overweight, Obesity
Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss
This study is a randomized, adaptive, parallel arm study. The treatment group will receive the Elira wearable patch system and provided instructions for use and advised to follow a 1200 calorie diet.
- Trial name
- NCT03299881
- Testing
- Transcutaneous Nerve Stimulator (TENS), Diet & Exercise
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Elira Therapeutics, Inc.
Obesity
A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight
This study is open to adults, aged 18 to 75 years, with overweight or obesity. People with body mass index (BMI) of 27 or higher to join the study. People who have diabetes cannot participate.
- Trial name
- NCT04667377
- Testing
- BI 456906
- Where
- 43 sites in United States, Australia and 10 more
- Volunteers
- 387 people
- Sponsor
- Boehringer Ingelheim
Obesity
A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes
The purpose of this study is to test the safety and effectiveness of JNJ-28431754 in promoting weight loss in patients who are overweight or obese and who do not have diabetes.
- Trial name
- NCT00650806
- Testing
- Canagliflozin (JNJ-28431754)
- Where
- 36 sites in United States, Puerto Rico
- Volunteers
- 376 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Obesity, Body Weight
Comparing the Efficacy of a Dual-Frequency LLLT Device With a Sham Device as a Therapy for Adipose Tissue Loss
The trial was designed to provide empirical evidence with which to compare the efficacy and safety of the invisa-RED Technology Elite Low-level Laser Therapy (LLLT) device with a sham device as a placebo, when both are used in…
- Conditions
- Obesity, Body Weight, Fat Burn, Cellulite
- Trial name
- NCT03811093
- Testing
- Care as Usual Group
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- IR Technology, LLC
Obesity
Retrospective Chart Review of the 5 & 2 & 2 and 4 & 2 & 1 Plans
The purpose of this study is to retrospectively and systematically review records of overweight and obese Medifast Weight Control Center (MWCC) members who have been assigned to the 5 \& 2 \& 2 Plan or the 4 \& 2 \& 1 Plan for…
- Trial name
- NCT02150837
- Testing
- 5 & 2 & 2 Plan, 4 & 2 & 1 Plan
- Where
- United States
- Volunteers
- 372 people, healthy volunteers welcome
- Sponsor
- Medifast, Inc.
Obesity
BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management
The purpose of this study is to assess the weight loss effect of lorcaserin at the end of the first year of treatment (Week 52) and to assess the ability of lorcaserin to maintain weight loss at the end of the second year of…
- Trial name
- NCT00395135
- Testing
- Lorcaserin 10 mg BID
- Where
- United States
- Volunteers
- 3,182 people
- Sponsor
- Eisai Inc.
Cachexia, Non-Small Cell Lung Cancer
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
The administration of Anamorelin HCl in patients with Non-Small Cell Lung Cancer-Cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength.
- Trial name
- NCT01395914
- Testing
- Anamorelin HCl
- Where
- 72 sites in United States, Australia and 15 more
- Volunteers
- 513 people
- Sponsor
- Helsinn Therapeutics (U.S.), Inc